EntryPoint Capital’s Keros Therapeutics KROS Stock Holding History

EntryPoint Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-11,535	Closed	-$183K	–	817
2024 Q4	$183K	Buy	+11,535	New	+$599K	0.08%	609
2024 Q1	–	Sell	-23	Closed	-$914	–	1595
2023 Q4	$914	Buy	+23	New	+$721	﹤0.01%	1290

Other funds holding KROS

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

EntryPoint Capital's KROS Position: Q1 2025 in Review

EntryPoint Capital sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 11,535 shares — an estimated $183K sold.

EntryPoint Capital first reported a position in KROS in Q4 2023 and held it in 2 quarters. The position peaked at $183K in Q4 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

EntryPoint Capital reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
EntryPoint Capital sold 11,535 Keros Therapeutics shares in Q1 2025, an estimated $183K.
EntryPoint Capital first reported a position in Keros Therapeutics in Q4 2023 and held it in 2 quarters.
EntryPoint Capital's Keros Therapeutics position peaked at $183K in Q4 2024.
156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on EntryPoint Capital's 13F filing for Q1 2025, filed 14 May 2025.